RxDoctor Payments DataLook up a doctor →

Ross Summerford, MD

Family Medicine · Tuscaloosa, ALNPI 1013354521

Payments from drug & device makers

$17,882in general payments, 2019–2025

Across 1,108 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Pfizer$2K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • AbbVie$1K
  • plus $8K from 40 others

What the payments were for

  • Food & beverage$17,882100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,882 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$227,530
Medicare patients
378
Services billed
6,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$157,875
FarxigaDapagliflozin Propanediol108$104,328
JardianceEmpagliflozin74$66,439
RybelsusSemaglutide43$64,778
MounjaroTirzepatide47$50,615
EliquisApixaban48$45,332
Trijardy XrEmpaglifloz/Linaglip/Metformin17$27,823
TrulicityDulaglutide14$24,488
VraylarCariprazine Hcl15$21,037
LinzessLinaclotide32$19,266
ProliaDenosumab11$18,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,230
AbrysvoRsv Vacc, Pref A And Pref B/Pf50$15,857
MyrbetriqMirabegron19$15,693
Spiriva RespimatTiotropium Bromide17$15,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,082$222,653144 claims
Boehringer IngelheimJardiance, Trijardy Xr, Spiriva Respimat, Glyxambi$1,372$117,889119 claims
AstraZenecaFarxiga$1,956$104,328108 claims
Lilly USA, LLCMounjaro, Trulicity$1,498$75,10361 claims
PfizerEliquis, Abrysvo, Premarin$1,536$65,194112 claims
AbbVieVraylar, Linzess, Synthroid$1,330$46,341135 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$956$31,30277 claims
MerckJanumet Xr, Januvia$430$24,03529 claims
AmgenProlia$1,142$18,76011 claims
Johnson & JohnsonXarelto$918$13,13717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →